1. Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases
   Javier Blanco-Rivero et al, 2020, Current Pharmaceutical Design CrossRef
2. Inhibition of Intracellular Type 10 Adenylyl Cyclase Protects Cortical Neurons Against Reperfusion-Induced Mitochondrial Injury and Apoptosis
   Megha Chagtoo et al, 2018, Molecular Neurobiology CrossRef
3. Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons
   Yousuf O. Ali et al, 2017, Scientific Reports CrossRef
4. Therapeutic implications of phosphorylation- and dephosphorylation-dependent factors of cAMP-response element-binding protein (CREB) in neurodegeneration
   Nilima Khakha et al, 2023, Pharmacological Reports CrossRef
5. Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington’s disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway
   Priyanka Saroj et al, 2021, Inflammopharmacology CrossRef
6. Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
   Shirin Z. Birjandi et al, 2021, Translational Stroke Research CrossRef
7. Protein kinase A negatively regulates VEGF-induced AMPK activation by phosphorylating CaMKK2 at serine 495
   Katrin Spengler et al, 2020, Biochemical Journal CrossRef
8. The phosphodiesterase type 2 inhibitor BAY 60‐7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity
   Ligia Mendes Soares et al, 2017, European Journal of Neuroscience CrossRef
9. Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage
   Qingjian Wu et al, 2017, Inflammation CrossRef
10. Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder
    Zhuoran Wang et al, 2018, Aging CrossRef
11. Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model
    Walyson Coelho Costa et al, 2023, International Immunopharmacology CrossRef
12. Therapeutic efficacy of rolipram delivered by PgP nanocarrier on secondary injury and motor function in a rat TBI model
    Christian Macks et al, 2022, Nanomedicine CrossRef
13. Transcriptional Regulators as Targets for Alcohol Pharmacotherapies
    Antonia M. Savarese et al, 2018, The Neuropharmacology of Alcohol CrossRef
14. Cyclic adenosine monophosphate in acute ischemic stroke: some to update, more to explore
    Meiying Xin et al, 2020, Journal of the Neurological Sciences CrossRef
15. Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review
    Saiqa Yasmeen et al, 2019, Cellular Signalling CrossRef